The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2012Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease
Objective/Rationale:
Fumaric acid esters have shown immuno-modulatory and neuroprotective effects in cell-based systems, pre-clinical models of disease and clinical trials in multiple sclerosis and... -
Clinical Intervention Awards, 2012Sublingually Administered APL-130277 Compared to Apokyn in Healthy Volunteers
Objective/Rationale:
Apomorphine is an under-utilized medication in Parkinson's disease (PD). Despite its strong efficacy as a rescue medication for intermittent "off" episodes in PD and its rapid... -
Therapeutics Development Initiative, 2012IMD-026259 - An Innovative Drug for Disease-Modifying Treatment of Parkinson´s Disease
Objective/Rationale:
IMD-026259 represents a proprietary highly potent and selective small molecule inhibitor of NF-kB pathway and 1 alpha (HIF-1alpha) mediated transcriptional activity. Comprehensive... -
MJFF Research Grant, 2012Gremlin-1, a Putative VTA-derived Neuroprotective Factor in Parkinson's Disease (Supplement)
Promising Outcomes of Original Grant:
We have previously postulated that the glycoprotein Gremlin has a neuroprotective role in PD. To test this hypothesis, we sought to develop a gremlin knockout pre... -
Target Validation, 2012Validation of Sirtuin 3 as a Neuroprotective Target in Parkinson’s Disease
Objective/Rationale:
Mitochondria are the major energy generators of a cell. Dysfunctional mitochondria are central to the pathology of Parkinson’s Disease (PD). We hypothesize that improving the... -
Biomarker Development, 2012Cleaved Cerebrospinal Fluid Proteins as Early Biomarkers for Detection of Parkinson’s Disease.
Objective/Rationale:
Parkinson’s disease is associated with the appearance of large, intracellular aggregates termed Lewy bodies consisting of damaged, truncated, aggregated and misfolded proteins...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.